The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.75
Bid: 32.50
Ask: 33.00
Change: -0.50 (-1.50%)
Spread: 0.50 (1.538%)
Open: 33.00
High: 33.25
Low: 32.75
Prev. Close: 33.25
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Modification of Partners' Agreements

14 May 2019 07:00

RNS Number : 8869Y
Duke Royalty Limited
14 May 2019
 

14 May 2019

 

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Modification of Terms with Recently Acquired Royalty Partners

 

Duke Royalty Limited (AIM: DUKE), a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, is pleased to announce modifications to the terms of the following agreements which will increase near term revenues for the Company.

 

The Company has reached agreements with royalty partners Welltel (Ireland) Limited ("Welltel"), a telecommunications services company, media company Pearl & Dean Cinemas Limited ("the Pearl & Dean Group"), and Xtremepush Limited ("Xtremepush"), a technology solutions company, all of which were acquired via the recent Capital Step acquisition, to modify the terms of existing agreements. This is expected to increase gross revenues to Duke by at least £3.7 million in aggregate over the next five years.

 

Capital Step was acquired by Duke Royalty in February 2019, prior to which it offered a 'unitranche' solution, which is a perpetual royalty paired with a senior secured loan, which amortises over a three to five year term. Pursuant to the existing arrangements with these three royalty partners, a total of £5.5 million of capital deployed amongst them was due to begin repayments in various instalments starting from December 2018, with the entire £5.5 million of capital expected to be repaid by 31 March 2022.

 

Modifications of terms have now been agreed; for Welltel and Xtremepush, the maturity dates of the senior loan facilities have been extended until 30 April 2024, when the full repayment of principal will be due. For the Pearl and Dean Group, the original agreement saw half of the royalty amortising over three years, and the other half as a perpetual term. The parties have agreed to make the entire amount a perpetual royalty, with the return calculated as a fixed percentage of gross revenues, subject to a floor and a cap. All other terms of the agreements remain the same.

 

As a result of removing the capital repayments, Duke has increased the gross revenues that it expects to receive, assuming the agreements are in place until 30 April 2024, by at least £3.7 million. By extending the royalty agreement in perpetuity, the actual revenue could exceed this figure depending on future revenue growth of the Pearl & Dean Group, as £3.7 million only includes the minimum contractual royalties (ie. the 'floor') due in the next five years. 

 

These modifications represent an increase of more than 25% to the Capital Step portfolio's expected revenues per year for the next five years and need no additional overhead costs. Importantly, these contract modifications are excluded from the 'performance related milestones for the period ended 31 March 2021' which the Capital Step portfolio needs to deliver in order to receive a deferred payment from Duke Royalty, as announced by the Company on 4th February.

 

Neil Johnson, CEO of Duke Royalty, said:

"We are pleased to agree these modifications, which means that our royalty partners can increase short term cash flow and Duke can maximise near term revenues. We recognised the strength and credit quality of the acquired royalty partners and the Board identified this as a way of unlocking value of the Capital Step royalty agreements for Duke Royalty shareholders. We are also looking at the opportunity to deploy further capital at accretive returns via follow-on investments into the acquired royalty partners and look forward to updating the market in due course."

 

**ENDS**

 

For further information, please contact www.dukeroyalty.com, or contact:

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon-Brookes

 

+44 (0) 1481 741 240

Cenkos Securities plc 

(Nominated Adviser and Broker)

 

Julian Morse / Michael Johnson / Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

Newgate Communications

(PR)

 

Elisabeth Cowell / Ian Silvera / Tom Carnegie

+44 (0) 20 3757 6880

Dukeroyalty@newgatecomms.com

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRBRGDUGSBBGCX
Date   Source Headline
30th Aug 20223:07 pmRNSHolding(s) in Company
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update
21st Jun 20227:00 amRNSInterim Dividend and Dividend Declaration
1st Jun 20224:25 pmRNSHolding(s) in Company
27th May 20229:08 amRNSDirector / PCA Dealings
26th May 20223:23 pmRNSResult of General Meeting and Issue of Equity
11th May 20227:05 amRNSRaises £20m through Placing and PrimaryBid Offer
10th May 20225:08 pmRNSPrimaryBid Offer
10th May 20224:44 pmRNSPlacing to raise a minimum of £15 million
28th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
20th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
11th Apr 20227:00 amRNSTrading Update
18th Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Mar 20227:00 amRNSIncreased Interim Dividend & Dividend Declaration
2nd Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
25th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Feb 20227:00 amRNSFurther re: Directorate Change
14th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
2nd Feb 20227:00 amRNSDirectorate Changes
1st Feb 202210:02 amRNSReplacement - Trading Update
1st Feb 20227:00 amRNSTrading Update
20th Jan 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
23rd Dec 20212:30 pmRNSHolding(s) in Company
23rd Dec 20217:01 amRNSTrading Update
23rd Dec 20217:00 amRNSFollow-on investment into existing Royalty Partner
22nd Dec 20213:52 pmRNSFollow-on investment into existing Royalty Partner
16th Dec 20217:00 amRNSNew Royalty Agreement
14th Dec 20217:00 amRNSIncreased Interim Dividend & Dividend Declaration
7th Dec 20217:00 amRNSEnters into Largest Royalty Agreement To Date
3rd Dec 20217:00 amRNSInterim Results
2nd Dec 20217:00 amRNSCompletion of £4.2 million Follow-On Investment
25th Nov 20217:00 amRNSNotice of Interim Results
29th Oct 20214:03 pmRNSLong Term Incentive Plan Awards
27th Oct 20217:01 amRNSFollow-On Investment into Existing Royalty Partner
27th Oct 20217:00 amRNSHolding(s) in Company
22nd Oct 20214:36 pmRNSResult of Annual General Meeting
16th Sep 20217:01 amRNSInterim Dividend and Dividend Declaration
16th Sep 20217:00 amRNSFinal Results
7th Sep 20217:00 amRNS£2.2m Follow-On Investment into Royalty Partner
2nd Sep 20217:00 amRNSHolding(s) in Company
17th Aug 20217:00 amRNSInvestor Presentation
11th Aug 20217:00 amRNSSuccessful Exit of Investment in Royalty Partner
10th Aug 20217:00 amRNSNotice of Results and Analyst Presentation
2nd Aug 20217:00 amRNSNew Royalty Agreement
26th Jul 20217:00 amRNSTrading Update
22nd Jul 20217:00 amRNSNew Royalty Agreement
1st Jul 20217:00 amRNSNew Royalty Agreement with Fairmed Healthcare AG
17th Jun 20217:00 amRNSInterim Dividend and Dividend Declaration
10th May 20217:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.